Iruxolum Mono (Collagenase Clostridium Histolyticum, Protease)

The collagenase enzyme hydrolyzes the peptide bonds of collagen and other extracellular matrix proteins within dead tissue. By breaking down this structural scaffold, the drug selectively removes necrotic material while sparing viable cells, thereby facilitating wound cleansing and subsequent repair.

The appropriate amount and frequency of Iruxolum Mono are determined by the treating clinician based on wound size, depth, and patient factors. No fixed dosing regimen is provided; the prescriber tailors application to each individual case.

Safety data for Iruxolum Mono in pregnancy or lactation are limited. The product should only be used if the prescriber judges that the potential benefit outweighs any possible risk to the fetus or infant.

To place an order, submit an enquiry on the Iruxolum Mono product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Iruxolum Mono offers enzymatic debridement, which is selective for necrotic tissue and generally less painful than mechanical methods. Compared with chemical agents such as povidone‑iodine, it targets collagen directly and preserves healthy tissue, though it may require careful monitoring for allergic reactions.

Store the product at ambient temperature, preferably below 25 °C. Keep it in the original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed when not in use.

Iruxolum Mono is applied topically to the wound surface by a qualified healthcare professional. The clinician spreads a thin, even layer over the necrotic area, following the prescribed frequency, and then covers the wound with an appropriate dressing as directed.

The most serious adverse events include severe allergic reactions such as anaphylaxis, unintended extensive tissue necrosis beyond the target area, and secondary infections that may develop if the wound is not properly monitored.

Patients with a known hypersensitivity to collagenase, protease enzymes, or any excipients in the formulation should avoid Iruxolum Mono. It is also contraindicated on healthy skin, mucous membranes, or in wounds lacking viable surrounding tissue.